Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective, Single-Center, Exploratory Phase II Clinical Study of Iparomlimab and Tuvonralimab (QL1706) Combined With Chemotherapy in the Treatment of Previously Untreated Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer

NCT07315854 is registered in ClinicalTrials.gov with Beijing Friendship Hospital as lead sponsor.

NCT NCT07315854
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07315854 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective, Single-Center, Exploratory Phase II Clinical Study of Iparomlimab and Tuvonralimab (QL1706) Combined With Chemotherapy in the Treatment of Previously Untreated Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer
Lead sponsor
Beijing Friendship Hospital
Phase
Phase 2
Overall status
Recruiting
Start date
November 4, 2025
Completion date
December 31, 2029
Enrollment
32 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

advanced gastric cancer, gastric cancer (gc), gastroesophageal junction cancer, metastatic gastric cancer